tiprankstipranks
Trending News
More News >

TransMedics price target raised to $125 from $105 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on TransMedics (TMDX) to $125 from $105 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that beat on the top and bottom lines. Management also raised full year sales guidance by more than the beat. Piper expects the guide will remain a key topic amongst investors, particularly as competitors enter TransMedics’ crucial liver market later this year.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1